The risk of nephrotic syndrome with non-VEGF inhibitory antineoplastic drugs: from viewpoint of the adverse event reports in Japan

Clin Exp Nephrol. 2021 Jan;25(1):97-98. doi: 10.1007/s10157-020-01957-x. Epub 2020 Aug 27.

Kouji Okada^{1

2}, Kensuke Usui^{3

4}, Daisuke Kikuchi⁴, Masanori Takahashi⁴, Yoshiteru Watanabe^{3

4}

¹ Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, 1-12-1 Fukumuro, Miyagino-ku, Sendai, Miyagi, 983-8512, Japan. kokada@tohoku-mpu.ac.jp.
² Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Miyagi, Japan. kokada@tohoku-mpu.ac.jp.
³ Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, 1-12-1 Fukumuro, Miyagino-ku, Sendai, Miyagi, 983-8512, Japan.
⁴ Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Miyagi, Japan.

No abstract available

Publication types